Advancing outcomes of metastatic HER2-positive breast cancer

Lancet. 2023 May 27;401(10390):1746-1747. doi: 10.1016/S0140-6736(23)00805-X. Epub 2023 Apr 20.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Female
  • Humans
  • Neoplasm Metastasis
  • Receptor, ErbB-2
  • Trastuzumab / therapeutic use

Substances

  • Trastuzumab
  • Receptor, ErbB-2